Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

Nature Medicine

Volumn 4, Issue 3, 1998, Pages 328-332

  Nestle, Frank O ^a   Alijagic, Selma ^b   Gilliet, Michel ^a   Sun, Yuansheng ^b   Grabbe, Stephan ^c   Dummer, Reinhard ^a   Burg, Günter ^a   Schadendorf, Dirk ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DACARBAZINE; INTERFERON; INTERLEUKIN 2; MELANOMA VACCINE; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HYPERTHERMIC THERAPY; INTRATUMORAL DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; REGIONAL PERFUSION; TREATMENT OUTCOME; VACCINATION;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; PEPTIDES; SKIN TESTS; T-LYMPHOCYTES, CYTOTOXIC; TOMOGRAPHY; VACCINATION;

EID: 0031941423     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0398-328     Document Type: Article

References (25)

1. MacKie, R.M. Melanoma prevention and early detection. Br. Med. Bull. 51 570-583 (1995).
2. Rosenberg, S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18, 175-182 (1997).
3. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991).
4. Flamand, V. et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24, 605-610 (1994).
5. Mayordomo, J.I. et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med. 1, 1297-1302 (1995).
6. Mayordomo, J.I. et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183, 1357-1365 (1996).
7. Paglia, P. et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183; 317-322 (1996).
8. Porgador, A. et al. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156, 2918-2926 (1996).
9. Shimizu, J. et al. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. J. Immunol. 142, 1053-1059 (1989).
10. Zitvogel, L. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87-97 (1996).
11. Celluzzi, C. et al. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283-287 (1996).
12. Marchand, M. et al. Tumor regression responses in melanoma patients with a peptide encoded by gene MAGE-3. Int. J. Cancer 63, 883-885 (1995).
13. Jäger, E. et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66, 162-169 (1996).
14. Cormier, J.N. et al. Enhancement of cellular immunity in melanoma patient immunized with a peptide from MART-1/Melan-A. Cancer J. Sci. Am. 3, 37-44 (1997).
15. Grabbe, S. et al. Dendritic cells as initiators of tumor immune responses - a possible strategy for tumor immunotherapy? Immunol. Today 16, 117-121 (1995).
16. Lanzavecchia, A. Identifying strategies for immune intervention. Science 260, 937-944 (1993).
17. Peters, J.H. et al. Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol. Today 17, 273-278 (1996).
18. Caux, C. et al. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360, 258-261 (1992).
19. Romani, N, et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83-93 (1994).
20. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor-alpha. J. Exp. Med. 179, 1109-111 (1994).
21. + help. J. Exp. Med. 186, 65-70 (1997).
22. Zinkernagel, R.M. et al. On immunological memory. Annu. Rev. Immunol. 14, 333-367. (1996).
23. Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells. Nature Med. 2, 52-58 (1996).
24. Mukherji, B. et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 92, 8078-802 (1995).
25. Alijagic, S. et al. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur. J. Immunol. 25, 3100-3107 (1995).